Global Infectious Diseases Therapeutics Market - Influenza, RSV, Chlamydia, and Gonorrhoea
Global Infectious Diseases Therapeutics Market - Influenza, RSV, Chlamydia, and Gonorrhoea
Persistent Unmet Need for Treatment Fuels Novel Antiviral/Antibacterial Drug Development
14-Feb-2014
North America
$3,950.00
Special Price $2,962.50 save 25 %
Description
This research service focuses on antibiotic/antibacterial therapeutics for the treatment of infection by blood-borne (sexually transmitted) bacteria, which include Chlamydia trachomatis and Neisseria gonorrhoea as well as antiviral therapeutics for infections by vector-borne pathogens such as the influenza virus and the human respiratory syncytial virus (RSV).This research service comprises of a product and pipeline assessment for marketed and investigational products and combination regimens for the treatment of Chlamydia trachomatis, Neisseria gonorrhoeae, Influenza and RSV infections. Segmentation by drug class is provided along with additional supporting information, such as clinical trial timelines, results, and epidemiology.
Table of Contents
Introduction
Introduction (continued)
Evolution of Standard of Care
Evolution of Standard of Care (continued)
Evolution of Standard of Care (continued)
Evolution of Standard of Care (continued)
Methodology and Scope
Market Overview—Segmentation
Market Overview—Segmentation (continued)
Market Overview—Segmentation (continued)
Market Overview—Segmentation (continued)
Market Overview—Segmentation (continued)
RSV—Market Segmentation
RSV—Competitive Landscape: Select Marketed Products and Products in Development
RSV—Key Marketed Products Synopsis
RSV Product Dashboard
RSV Product Dashboard (continued)
RSV—Pipeline Synopsis
RSV—Pipeline Synopsis (continued)
RSV—Major Ongoing/Recently Completed Clinical Trials
RSV—Major Ongoing/Recently Completed Clinical Trials (continued)
RSV—Major Ongoing/Recently Completed Clinical Trials (continued)
RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings
RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
RSV—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
RSV—Timeline of Key Events
RSV—Key Company to Watch
RSV—Key Companies with Best Practices
RSV—New Market Opportunities
RSV—New Market Opportunities (continued)
RSV—Merger, Acquisition, and Partnership Assessment
Influenza—Market Segmentation
Influenza—Competitive Landscape: Select Marketed Products and Products in Development
Influenza Antivirals—Key Marketed Products Synopsis
Influenza Antivirals—Key Marketed Products Synopsis (continued)
Influenza Antivirals—Key Marketed Products Synopsis (continued)
Influenza Antivirals—Product Dashboard
Influenza Antivirals—Product Dashboard (continued)
Influenza Antivirals—Product Dashboard (continued)
Influenza Antivirals—Pipeline Synopsis
Influenza Antivirals—Pipeline Synopsis (continued)
Influenza Antivirals—Pipeline Synopsis (continued)
Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials
Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials (continued)
Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings
Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Influenza Antivirals—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Influenza Antivirals—Timeline of Key Events
Influenza Vaccines—Key Marketed Products Synopsis
Influenza Vaccines—Key Marketed Products Synopsis (continued)
Influenza Vaccines—Key Marketed Products Synopsis (continued)
Influenza Vaccines—Key Marketed Products Synopsis (continued)
Influenza Vaccines—Key Marketed Products Synopsis (continued)
Influenza Vaccines—Key Marketed Products Synopsis (continued)
Influenza Vaccines—Pipeline Synopsis
Influenza Vaccines—Pipeline Synopsis (continued)
Influenza Vaccines—Pipeline Synopsis (continued)
Influenza Vaccines—Pipeline Synopsis (continued)
Influenza Vaccines—Key Companies to Watch
Influenza Vaccines—Merger, Acquisition and Partnership Assessment
Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)
Influenza Vaccines—Merger, Acquisition and Partnership Assessment
Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)
Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)
Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)
Influenza Vaccines—Merger, Acquisition and Partnership Assessment (continued)
Chlamydia—Market Segmentation
Chlamydia—Treatment Regimen
Chlamydia—Treatment Regimen (continued)
Chlamydia—Treatment Regimen (continued)
Chlamydia—Competitive Landscape: Select Marketed Products and Products in Development
Chlamydia—Key Marketed Products Synopsis
Chlamydia—Key Marketed Products Synopsis (continued)
Chlamydia—Pipeline Synopsis
Chlamydia—Major Ongoing/Recently Completed Clinical Trials
Chlamydia—Major Ongoing/Recently Completed Clinical Trials (continued)
Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings
Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Chlamydia—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Chlamydia—Timeline of Key Events
Chlamydia—Key Company to Watch
Gonorrhoea—Market Segmentation
Gonorrhoea—Treatment Regimen
Gonorrhoea—Treatment Regimen (continued)
Gonorrhoea—Treatment Regimen (continued)
Gonorrhoea—Treatment Regimen (continued)
Gonorrhoea—Competitive Landscape: Select Marketed Products and Products in Development
Gonorrhoea—Key Marketed Products Synopsis
Gonorrhoea—Key Marketed Products Synopsis (continued)
Gonorrhoea—Key Marketed Products Synopsis (continued)
Gonorrhoea—Key Marketed Products Synopsis (continued)
Gonorrhoea—Pipeline Synopsis
Gonorrhoea—Pipeline Synopsis (continued)
Gonorrhoea—Major Ongoing/Recently Completed Clinical Trials
Gonorrhoea—Major Ongoing/Recently Completed Clinical Trials Detailed Findings
Gonorrhoea—Major Ongoing/Recently Completed Clinical Trials Detailed Findings (continued)
Gonorrhoea—Timeline of Key Events
Gonorrhoea—Key Company to Watch
Legal Disclaimer
Disease Characteristics
Disease Characteristics (continued)
Disease Characteristics (continued)
Disease Characteristics (continued)
The Frost & Sullivan Story
Value Proposition
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
No Index | No |
---|---|
Podcast | No |
Author | Aiswariya Chidambaram |
WIP Number | M9B7-01-00-00-00 |
Is Prebook | No |